The MARIA trial, sponsored by University Hospital, Tours, aimed to explore the role of microglial activation in Amyotrophic Lateral Sclerosis (ALS) using the radiopharmaceutical [18F]DPA714 as a biomarker for neuroinflammation. The study's withdrawal due to recruitment challenges highlights potential difficulties in patient enrollment for ALS-related trials, which could impact timelines and costs. The focus on neuroinflammation positions this asset within a growing market for ALS therapies, particularly as the understanding of neuroinflammatory mechanisms evolves. Companies developing similar imaging agents or therapies targeting neuroinflammation may represent both competition and collaboration opportunities. The insights gained could inform future drug development and patient stratification strategies.